Chong Kun Dang announced on the 8th that it has applied to the MFDS for approval of the conditional marketing authorization (CMA) and phase 3 clinical trial plan of Nafabelltan (Nafamostat) as a treatment for COVID-19 for patients with severe and high risk.

Nafabelltan is a drug used as a therapeutic agent for acute pancreatitis and as an anticoagulant. Nafabelltan inhibits the proteolytic enzyme TMPRSS2, which is known to be involved in the cell penetration process of COVID-19. Chong Kun Dang confirmed the possibility of developing it as a COVID-19 treatment in a drug re-creation study by Institut Pasteur Korea, and has been promoting the development of COVID-19 treatment with Institut Pasteur Korea a